Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
OR
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease

open label

see: http://clinicaltrials.gov/ct2/show/N...urturin&rank=1
Curently recruiting at :
United States, New York
Mount Sinai Medical Center

United States, Georgia
Emory University
Not yet recruiting
Atlanta, Georgia, United States
Principal Investigator: Nicholas M. Boulis, M.D.
Sub-Investigator: Mahlon R. DeLong, M.D

There aren't enough slots for all of the sham surgery participants but the first up is a forum member who got sham surgery first time around.